| Assay ID | Title | Year | Journal | Article |
|---|
| AID1477341 | Inhibition of JAK3 (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477329 | Inhibition of aurora A (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477307 | Plasma concentration in BALB/c mouse at 2.5 mg/kg, iv at 0.083 hrs by LC/MS-MS analysis | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315315 | Antiproliferative activity against human HCT116 cells assessed as reduction in diameter of spheroids at 1 uM after 5 days | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1317344 | Inhibition of human recombinant CDK5/p25 expressed in baculovirus infected Sf9 insect cells after 30 mins by [gamma-33P]ATP based scintillation counting analysis | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
| Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
| AID1477339 | Inhibition of CHK1 (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477331 | Inhibition of IRR (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477365 | Inhibition of DYRK1a (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477351 | Inhibition of IRR (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477366 | Inhibition of LCK (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315301 | Inhibition of recombinant GST-CDK5/p25 expressed in Escherichia coli | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477364 | Inhibition of MST4 (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315305 | Inhibition of rat recombinant GST-DYRK1A expressed in Escherichia coli | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477337 | Inhibition of PI3Kalpha (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477355 | Inhibition of VEGFR1 (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477390 | Antiproliferative activity against human T47D cells after 72 hrs by SRB assay | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477389 | Antiproliferative activity against human MDA-MB-468 cells | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477342 | Inhibition of JNK3 (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477333 | Inhibition of S6K1 (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315304 | Inhibition of pig CK1delta/CK1epsilon | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477348 | Inhibition of NEK6 (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315311 | Inhibition of human CDK mediated retinoblastoma protein phosphorylation in SHSY5Y cells after 24 hrs by Western blotting technique | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477356 | Inhibition of IKKbeta (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477350 | Inhibition of GSK3b (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315303 | Inhibition of pig GSK-3-alpha/GSK-3beta | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477357 | Inhibition of PI3Kalpha (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477336 | Inhibition of IKKbeta (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477335 | Inhibition of VEGFR1 (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477354 | Inhibition of SGK (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315313 | Inhibition of CDK mediated human RNA polymerase 2 phosphorylation in SHSY5Y cells after 24 hrs by Western blotting technique | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477314 | Plasma concentration in BALB/c mouse at 2.5 mg/kg, iv at 2 hrs by LC/MS-MS analysis | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477340 | Inhibition of CSK (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477361 | Inhibition of JAK3 (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477301 | Inhibition of CDK9/cyclin T (unknown origin) using YSPTSPSYSPTSPSYSPTSPKKK as substrate after 30 mins in presence of [33P]-gamma-ATP | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315308 | Survival of human GBM cells after 48 hrs by neutral red reduction assay | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477345 | Inhibition of MST4 (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315309 | Survival of human KMS11 cells after 48 hrs by neutral red reduction assay | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477362 | Inhibition of JNK3 (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477312 | Plasma concentration in BALB/c mouse at 2.5 mg/kg, iv at 1 hr by LC/MS-MS analysis | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477338 | Inhibition of BRK (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315312 | Inhibition of CDK mediated human PP1alpha phosphorylation in SHSY5Y cells after 24 hrs by Western blotting technique | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477392 | Antiproliferative activity against human MCF7 cells | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315299 | Inhibition of starfish oocyte CDK1/cyclin B | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477352 | Inhibition of PLK1 (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477298 | Antiproliferative activity against human SH-SY5Y cells after 24 hrs by MTT assay | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477332 | Inhibition of PLK1 (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477359 | Inhibition of CHK1 (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477334 | Inhibition of SGK (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477394 | Antiproliferative activity against HEK cells | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477360 | Inhibition of CSK (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315310 | Survival of human LS174T cells after 48 hrs by MTS reduction assay | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477316 | Plasma concentration in BALB/c mouse at 2.5 mg/kg, iv at 4 hrs by LC/MS-MS analysis | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477347 | Inhibition of LCK (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315306 | Survival of human SHSY5Y cells after 48 hrs by MTS reduction assay | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477346 | Inhibition of DYRK1a (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477297 | Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477396 | Antitumor activity against mouse 4T1 cells allografted in Balb/C mouse assessed as tumor growth inhibition at 15 mg/kg, iv administered every 3 days for 21 days measured 2 times for every week during dosing relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477367 | Inhibition of NEK6 (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477349 | Inhibition of aurora A (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315314 | Antiproliferative activity against human HCT116 cells after 5 days | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID315302 | Inhibition of human recombinant CDK9/cyclin T expressed in insect cells | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1317345 | Inhibition of human recombinant CDK9/cyclin T expressed in baculovirus infected Sf9 insect cells using pRB (773 to 928 residues) as substrate after 30 mins by [gamma-33P]ATP based scintillation counting analysis | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
| Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
| AID1477358 | Inhibition of BRK (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477330 | Inhibition of GSK3b (unknown origin) at 100 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315307 | Survival of human HEK293 cells after 48 hrs by MTS reduction assay | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477310 | Plasma concentration in BALB/c mouse at 2.5 mg/kg, iv at 0.5 hrs by LC/MS-MS analysis | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477299 | Inhibition of CDK2/cyclin A (unknown origin) using histone H1 as substrate after 30 mins in presence of [33P]-gamma-ATP | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477393 | Antiproliferative activity against mouse 4T1 cells after 24 hrs by MTT assay | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1317342 | Inhibition of M-phase starfish oocytes CDK1/cyclin B after 30 mins by [gamma-33P]ATP based scintillation counting analysis | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
| Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
| AID1477388 | Antiproliferative activity against human MDA-MB-231 cells | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1317343 | Inhibition of human recombinant CDK2/cyclin A after 30 mins by [gamma-33P]ATP based scintillation counting analysis | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
| Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
| AID1477391 | Antiproliferative activity against human BT549 cells | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477395 | Selectivity ratio of IC50 for HEK cells to IC50 for human MCF7 cells | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID315300 | Inhibition of human recombinant CDK2/cyclin A expressed in insect cells | 2008 | Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. |
| AID1477308 | Plasma concentration in BALB/c mouse at 2.5 mg/kg, iv at 0.25 hrs by LC/MS-MS analysis | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| AID1477353 | Inhibition of S6K1 (unknown origin) at 500 nM relative to control | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
| Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |